Lataa...
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination
Background During development of an A/H1N1 pandemic influenza vaccine, this study was performed to identify the antigen and adjuvant content which would provide optimal antibody response and persistence in adults and the elderly. Dose-sparing strategies, such as inclusion of adjuvants, are critical...
Tallennettuna:
| Julkaisussa: | Hum Vaccin Immunother |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4896790/ https://ncbi.nlm.nih.gov/pubmed/25424947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.29393 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|